MaaT Pharma S.A.
MAAT.PA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.35M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $17.35 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-1.95 |
| Beta | 0.41 |
| Outstanding Shares | 18,857,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.48 |
|---|---|
| PEG | -2.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
September 29, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$1.08 M
Consensus analyst estimateNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$1.23 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About MaaT Pharma S.A.
56 employees
CEO: Herve Affagard
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, ...